Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …

Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …

Progressive multiple sclerosis (MS) is characterized by unrelenting neurodegeneration,
which causes cumulative disability and is refractory to current treatments. Drug development …

Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple
sclerosis (MS), but their precise roles are unclear. In this Review, we provide an overview of …

Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …

Background No approved therapies exist for neuromyelitis optica spectrum disorder
(NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes …

Background The monoclonal antibody ublituximab enhances antibody-dependent cellular
cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of …

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central
nervous system afflicting nearly three million individuals worldwide. Neuroimmune …